Advanced Malignant Solid NeoplasmPhase 3NCT04939090
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
A Phase 3 study testing Olanzapine, Megestrol Acetate and Questionnaire Administration in people with Advanced Malignant Solid Neoplasm and Anorexia, run by Alliance for Clinical Trials in Oncology at 293 sites in United States.
Trial summary
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
- What is being tested?
- Olanzapine, Megestrol Acetate and Questionnaire Administration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 227 participants
- Where
- 293 sitesUnited States
- Study dates
- 3 Jan 2022to 31 Dec 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- Diagnosis of advanced cancer
- Patient-reported 2-month weight loss of at least 5 pounds (2.3 kilograms) and/or physician-estimated caloric intake of less than 20 calories/kilogram of body weight per day
- The patient must perceive loss of appetite and/or weight as a problem; and have an appetite score of 4 or worse on the "Please rate your appetite…." question that requires a patient response on a 0-10 numeric rating scale
- Not receiving ongoing tube feedings or parenteral nutrition at the time of registration
- Not currently using systemic adrenal steroids (with the exception of short-term dexamethasone within 3 days of chemotherapy for control of chemotherapy side effects)
Show all 25Show fewer
- No use of androgens, progesterone analogs, or other appetite stimulants within the past month
- Patient should not have poorly controlled hypertension or congestive heart failure at registration
- Patient should not have an obstruction of the alimentary canal, malabsorption, or intractable vomiting (defined as vomiting more than 3 times per day over the preceding week)
- Not currently using olanzapine for another medical condition or had previously used olanzapine for chronic nausea or for any pre-existing psychotic disorder
- Patient should not have had a previous blood clot at any time in the past
- No history of poorly controlled diabetes
- No symptomatic leptomeningeal disease or known brain metastases as these patients may have difficulty taking oral medications
- No history of hypersensitivity to olanzapine or megestrol acetate
- No COVID-19 infection in the past that, in the opinion of the treating physician, had left patients with compromised taste, which has not resolved at the time of registration
- Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration is required
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- Estimated life expectancy of 3 months or longer
- Serum creatinine =< 2.0 mg/dL
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
- Fasting glucose < 140 mg/dL
- Granulocytes > 1000/hpf
- No treatment with another antipsychotic agent, such as risperidone, quetiapine, clozapine, butyrophenone within 30 days of enrollment
- In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English or Spanish. Sites seeking to enroll Spanish-speaking patients should have access to Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish, and to conduct the weekly phone calls
Who cannot join
- Psychiatric illness which would prevent the patient from giving informed consent
- Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Patients who cannot swallow oral formulations of the agents
- Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
- No presence of a hormone-sensitive tumor, such as breast, endometrial, or prostate cancer (this exclusion criterion is intended to circumvent any confounding antineoplastic effects of megestrol acetate)
Trial locations and contacts
293 sites in 1 country.
293 sites in 1 country
United States293 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii, 96706
Hendrick Medical Center
Abilene, Texas, 79601
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic - Ames
Ames, Iowa, 50010
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Duluth Clinic Ashland
Ashland, Wisconsin, 54806
Piedmont Hospital
Atlanta, Georgia, 30309
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
Rush-Copley Medical Center
Aurora, Illinois, 60504
Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland, 21244
Baptist Hospitals of Southeast Texas Cancer Center
Beaumont, Texas, 77701
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
ThedaCare Cancer Care - Berlin
Berlin, Wisconsin, 54923
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Billings Clinic Cancer Center
Billings, Montana, 59101
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
McFarland Clinic - Boone
Boone, Iowa, 50036
Tufts Medical Center
Boston, Massachusetts, 02111
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Trinity Health Medical Center - Brighton
Brighton, Michigan, 48114
Bristol Regional Medical Center
Bristol, Tennessee, 37620
Ballad Health Cancer Care - Bristol
Bristol, Virginia, 24201
University of Vermont Medical Center
Burlington, Vermont, 05401
University of Vermont and State Agricultural College
Burlington, Vermont, 05405
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Illinois CancerCare-Canton
Canton, Illinois, 61520
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, 48188
Trinity Health Medical Center - Canton
Canton, Michigan, 48188
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado, 80112
Centralia Oncology Clinic
Centralia, Illinois, 62801
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Atrium Health Pineville/LCI-Pineville
Charlotte, North Carolina, 28210
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28262
Chelsea Hospital
Chelsea, Michigan, 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, 48118
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
Northwestern University
Chicago, Illinois, 60611
Morton Plant Hospital
Clearwater, Florida, 33756
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, 38017
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, 39705
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
Northwest Cancer Center - Main Campus
Crown Point, Indiana, 46307
UT Southwestern Simmons Cancer Center - RedBird
Dallas, Texas, 75237
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Carle at The Riverfront
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Halifax Health Medical Center-Centers for Oncology
Daytona Beach, Florida, 32114
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Essentia Health - Deer River Clinic
Deer River, Minnesota, 56636
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Henry Ford Health Saint John Hospital
Detroit, Michigan, 48236
Essentia Health Saint Mary's - Detroit Lakes Clinic
Detroit Lakes, Minnesota, 56501
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Epic Care-Dublin
Dublin, California, 94568
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Saint Luke's Hospital of Duluth
Duluth, Minnesota, 55805
Northwest Oncology LLC
Dyer, Indiana, 46311
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
Henry Ford River District Hospital
East China Township, Michigan, 48054
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado, 80113
Rocky Mountain Cancer Centers - Swedish
Englewood, Colorado, 80113
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Exeter Hospital
Exeter, New Hampshire, 03833
Essentia Health Cancer Center-South University Clinic
Fargo, North Dakota, 58103
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Piedmont Fayette Hospital
Fayetteville, Georgia, 30214
Hunterdon Medical Center
Flemington, New Jersey, 08822
Cancer Hematology Centers - Flint
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Levine Cancer Institute - Rutherford
Forest City, North Carolina, 28043
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, 50501
Regional Cancer Center-Lee Memorial Health System
Fort Myers, Florida, 33905
Tarrant County Hospital District/JPS Health Network
Fort Worth, Texas, 76104
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth, Texas, 76104
Essentia Health - Fosston
Fosston, Minnesota, 56542
Washington Hospital
Fremont, California, 94538
Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg, Maryland, 20879
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Levine Cancer Institute-Gaston
Gastonia, North Carolina, 28054
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Tidelands Georgetown Memorial Hospital
Georgetown, South Carolina, 29440
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona, 85297
Glens Falls Hospital
Glens Falls, New York, 12801
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois, 60026
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
CTCA at Western Regional Medical Center
Goodyear, Arizona, 85338
Altru Cancer Center
Grand Forks, North Dakota, 58201
Grand Valley Oncology
Grand Junction, Colorado, 81505
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois, 60030
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
East Carolina University
Greenville, North Carolina, 27834
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Baptist Cancer Center-Grenada
Grenada, Mississippi, 38901
Henry Ford Saint John Hospital - Van Elslander
Grosse Pointe Woods, Michigan, 48236
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Essentia Health Hibbing Clinic
Hibbing, Minnesota, 55746
Northwest Cancer Center - Hobart
Hobart, Indiana, 46342
Saint Mary Medical Center
Hobart, Indiana, 46342
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Saint Catherine Hospital
Indianapolis, Indiana, 46312
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
Queens Hospital Center
Jamaica, New York, 11432
Essentia Health - Jamestown Clinic
Jamestown, North Dakota, 58401
McFarland Clinic - Jefferson
Jefferson, Iowa, 50129
Regional Cancer Center at Johnson City Medical Center
Johnson City, Tennessee, 37604
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, 72401
Castle Medical Center
Kailua, Hawaii, 96734
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Ballad Health Cancer Care - Kingsport
Kingsport, Tennessee, 37660
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Kaiser Permanente - Largo Medical Center
Largo, Maryland, 20774
Memorial Medical Center-Las Cruces
Las Cruces, New Mexico, 88011
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Saint Joseph Hospital East
Lexington, Kentucky, 40509
Saint Rita's Medical Center
Lima, Ohio, 45801
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Kaiser Permanente Lutherville - Timonium Medical Center
Lutherville, Maryland, 21093
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Henry Ford Saint John Hospital - Macomb Medical
Macomb, Michigan, 48044
McFarland Clinic - Marshalltown
Marshalltown, Iowa, 50158
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Kaiser Permanente Tysons Corner Medical Center
McLean, Virginia, 22102
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
Beebe South Coastal Health Campus
Millville, Delaware, 19967
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Minneapolis VA Medical Center
Minneapolis, Minnesota, 55417
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455
Atrium Health Union/LCI-Union
Monroe, North Carolina, 28112
The Community Hospital
Munster, Indiana, 46321
Women's Diagnostic Center - Munster
Munster, Indiana, 46321
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, 83687
ThedaCare Regional Medical Center - Neenah
Neenah, Wisconsin, 54956
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi, 38652
ThedaCare Cancer Care - New London
New London, Wisconsin, 54961
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Piedmont Newnan Hospital
Newnan, Georgia, 30265
Carle BroMenn Medical Center
Normal, Illinois, 61761
Carle Cancer Institute Normal
Normal, Illinois, 61761
Ballad Health Cancer Care - Norton
Norton, Virginia, 24273
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Northwestern Medicine Oak Brook
Oak Brook, Illinois, 60523
Drexel Town Square Health Center
Oak Creek, Wisconsin, 53154
Bay Area Tumor Institute
Oakland, California, 94609
Northwestern Medicine Orland Park
Orland Park, Illinois, 60462
Halifax Health Center for Oncology - Ormond Beach
Ormond Beach, Florida, 32174
ThedaCare Cancer Care - Oshkosh
Oshkosh, Wisconsin, 54904
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Essentia Health - Park Rapids
Park Rapids, Minnesota, 56470
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Arizona Center for Cancer Care-Peoria
Peoria, Arizona, 85381
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Illinois CancerCare-Peru
Peru, Illinois, 61354
Arizona Center for Cancer Care - Phoenix
Phoenix, Arizona, 85027
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, 28374
South Florida Baptist Hospital
Plant City, Florida, 33563
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan, 48341
Halifax Health Center for Oncology - Port Orange
Port Orange, Florida, 32127
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, 83854
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, 17901
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Valley Medical Center
Renton, Washington, 98055
UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas, 75080
West Suburban Medical Center
River Forest, Illinois, 60305
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Levine Cancer Institute-Rock Hill
Rock Hill, South Carolina, 29732
Mease Countryside Hospital
Safety Harbor, Florida, 34695
MyMichigan Medical Center Saginaw
Saginaw, Michigan, 48601
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Zuckerberg San Francisco General Hospital
San Francisco, California, 94110
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, 83864
Essentia Health Sandstone
Sandstone, Minnesota, 55072
Dominican Santa Cruz Hospital
Santa Cruz, California, 95065
Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania, 18840
Arizona Center for Cancer Care - Osborn
Scottsdale, Arizona, 85251
Arizona Center for Cancer Care - Scottsdale
Scottsdale, Arizona, 85258
Community Medical Center
Scranton, Pennsylvania, 18510
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
ThedaCare Cancer Care - Shawano
Shawano, Wisconsin, 54166
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi, 38671
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62702
Springfield Memorial Hospital
Springfield, Illinois, 62781
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Saint Anthony's Hospital Cancer Care Center
St. Petersburg, Florida, 33705
Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan, 48312
Lakeview Hospital
Stillwater, Minnesota, 55082
Piedmont Henry Hospital
Stockbridge, Georgia, 30281
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235-1495
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri, 63127
Arizona Center for Cancer Care-Surprise
Surprise, Arizona, 85374
MyMichigan Medical Center Tawas
Tawas City, Michigan, 48764
James J Peters VA Medical Center
The Bronx, New York, 10468
Sanford Thief River Falls Medical Center
Thief River Falls, Minnesota, 56701
Rocky Mountain Cancer Centers-Thornton
Thornton, Colorado, 80260
UM Saint Joseph Medical Center
Towson, Maryland, 21204
Carle Cancer Center
Urbana, Illinois, 61801
Northwest Cancer Center - Valparaiso
Valparaiso, Indiana, 46383
Essentia Health Virginia Clinic
Virginia, Minnesota, 55792
Epic Care Cyberknife Center
Walnut Creek, California, 94597
Henry Ford Health Warren Hospital
Warren, Michigan, 48093
Henry Ford Warren Hospital - GLCMS
Warren, Michigan, 48093
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Illinois CancerCare - Washington
Washington, Illinois, 61571
Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
Washington, North Carolina, 27889
Kaiser Permanente-Capitol Hill Medical Center
Washington D.C., District of Columbia, 20002
ThedaCare Cancer Care - Waupaca
Waupaca, Wisconsin, 54981
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin, 53095
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Rice Memorial Hospital
Willmar, Minnesota, 56201
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
Kaiser Permanente-Caton Hill Medical Center
Woodbridge, Virginia, 22192
Sanford Cancer Center Worthington
Worthington, Minnesota, 56187
Rush-Copley Healthcare Center
Yorkville, Illinois, 60560
Huron Gastroenterology PC
Ypsilanti, Michigan, 48106
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan, 48197
About this study
Official title: A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Read the detailed description
The primary and secondary objectives of the study:
PRIMARY OBJECTIVE:
- To determine whether olanzapine leads to greater appetite improvement from baseline in cancer patients suffering from anorexia compared to megestrol acetate using the 0-10 numerical rating scale (NRS).
SECONDARY OBJECTIVES:
- To determine whether olanzapine leads to a greater proportion of patients who report a 5% or greater weight gain from baseline compared to megestrol acetate.
II. To compare change in cachexia/anorexia symptoms with olanzapine compared to megestrol acetate using the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS) instrument.
OUTLINE: Patient are randomized to 1 of 2 arms.
ARM I: Patients receive olanzapine orally (PO) once daily (QD) for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity.
ARM II: Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity.
- Being tested
- Olanzapine, Megestrol Acetate, Questionnaire Administration
- Medical subject headings
- Anorexia, Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OlanzapineDrug
Given PO
Megestrol AcetateDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (olanzapine) | Experimental | Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity. Receives: Drug: Olanzapine; Other: Questionnaire Administration |
| Arm II (megestrol acetate) | Active comparator | Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity. Receives: Drug: Megestrol Acetate; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in appetite
Will be compared between the two study groups (olanzapine versus megestrol acetate) using a 0-10 numerical rating scale. Will be summarized by mean (standard deviation [SD]) and median (range) by treatment arm. The difference in appetite change from baseline to 4 weeks of treatment between arms will be estimated along with a 95% confidence interval and will be compared using a t-test or Wilcoxon rank-sum test as appropriate.
Measured: Baseline up to 4 weeks
Secondary outcomes (2)
Proportion of patients who report a 5% or greater weight gain
The proportion of patients with a 5% or greater weight gain from baseline will be calculated for each arm. The difference in proportion of patients with 5% or greater weight gain between the arms will be estimated along with a 95% confidence interval using a normal approximation of the binomial distribution and will be compared using a Chi-squared test.
Measured: Baseline up to 4 weeks
Change in well-being status and cachexia/anorexia symptoms
Responses to the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS) questionnaire will be scored according to the established algorithm. The total score of the FAACT-A/CS will be summarized weekly and the change from baseline to 4 weeks will be compared between the treatment arms using the same methods described for the primary endpoint.
Measured: Baseline up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2021
- Study start3 Jan 2022
- Primary completion14 Apr 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Malignant Solid NeoplasmStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 227 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Aminah Jatoi, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04939090
- Sponsor's protocol ID
- A222004
- Other IDs
- NCI-2021-03303, UG1CA189823
- Status last verified
- Jul 2026
- First submitted
- 17 Jun 2021
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
- ClinicalTrials.gov ID
- NCT04939090
- Acronym / sponsor ID
- A222004
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 227 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 3 Jan 2022 (actual)
- Primary completion
- 14 Apr 2026 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 25 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Detailed description
The primary and secondary objectives of the study:
PRIMARY OBJECTIVE:
- To determine whether olanzapine leads to greater appetite improvement from baseline in cancer patients suffering from anorexia compared to megestrol acetate using the 0-10 numerical rating scale (NRS).
SECONDARY OBJECTIVES:
- To determine whether olanzapine leads to a greater proportion of patients who report a 5% or greater weight gain from baseline compared to megestrol acetate.
II. To compare change in cachexia/anorexia symptoms with olanzapine compared to megestrol acetate using the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS) instrument.
OUTLINE: Patient are randomized to 1 of 2 arms.
ARM I: Patients receive olanzapine orally (PO) once daily (QD) for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity.
ARM II: Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (olanzapine) | Experimental | Drug: Olanzapine, Other: Questionnaire AdministrationPatients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity. |
| Arm II (megestrol acetate) | Active comparator | Drug: Megestrol Acetate, Other: Questionnaire AdministrationPatients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- Diagnosis of advanced cancer
- Patient-reported 2-month weight loss of at least 5 pounds (2.3 kilograms) and/or physician-estimated caloric intake of less than 20 calories/kilogram of body weight per day
- The patient must perceive loss of appetite and/or weight as a problem; and have an appetite score of 4 or worse on the "Please rate your appetite…." question that requires a patient response on a 0-10 numeric rating scale
- Not receiving ongoing tube feedings or parenteral nutrition at the time of registration
Key exclusion criteria (5 listed)
- Psychiatric illness which would prevent the patient from giving informed consent
- Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Patients who cannot swallow oral formulations of the agents
- Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
- No presence of a hormone-sensitive tumor, such as breast, endometrial, or prostate cancer (this exclusion criterion is intended to circumvent any confounding antineoplastic effects of megestrol acetate)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OlanzapineGiven PO | Drug | Arm I (olanzapine) |
| Megestrol AcetateGiven PO | Drug | Arm II (megestrol acetate) |
| Questionnaire AdministrationAncillary studies | Other | Arm I (olanzapine), Arm II (megestrol acetate) |
Primary outcome
Change in appetite
Time frame: Baseline up to 4 weeks
Will be compared between the two study groups (olanzapine versus megestrol acetate) using a 0-10 numerical rating scale. Will be summarized by mean (standard deviation [SD]) and median (range) by treatment arm. The difference in appetite change from baseline to 4 weeks of treatment between arms will be estimated along with a 95% confidence interval and will be compared using a t-test or Wilcoxon rank-sum test as appropriate.
2 secondary outcomes
Proportion of patients who report a 5% or greater weight gain
Time frame: Baseline up to 4 weeks
Change in well-being status and cachexia/anorexia symptoms
Time frame: Baseline up to 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: Yes
Related trials for Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingObservational study
Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program
Advanced Solid Tumor
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aminah Jatoi, MD study chair
Mayo Clinic
293 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Olanzapine, Megestrol Acetate and Questionnaire Administration in people with Advanced Malignant Solid Neoplasm and Anorexia, run by Alliance for Clinical Trials in Oncology at 293 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 293 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in appetite (time frame: Baseline up to 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.